

Tigecycline

Tigecycline is a tetracycline derivative. It has *in vitro* activity against most strains of staphylococci and streptococci (including MRSA and VRE), anaerobes, and many gram-negative organisms with the exception of *Pseudomonas* and *Proteus*. It is FDA-approved for treatment of skin and skin-structure infections and intraabdominal infections. Peak serum concentrations do not exceed 1 mcg/mL which limits its use for treatment of bacteremia.

Acceptable uses (Infectious Disease or ASP approval required)

- Management of intra-abdominal infections in patients with contraindications to both beta-lactams and fluoroquinolones
- Management of infections due to multi-drug resistant gram-negative organisms including *Acinetobacter* on a case-by-case basis
- Salvage therapy for MRSA or VRE infections on a case-by-case basis

Unacceptable use

- Bacteremia and endocarditis
- Tigecycline should not be used to treat pneumonia, as unacceptably high failure rates have been reported.

Dose

- 100 mg IV once, then 50 mg IV q12h

Toxicity

- Nausea/vomiting in 25% of recipients
- Monitoring: LFTs weekly